Fig 1: Overall survival analysis in first-line treatment of mCRC patients with chemotherapy plus bevacizumab according to basal VEGF-A and ACE plasma levels. Three prognostic risk groups were defined according to ACE and VEGF-A plasma level tertiles: high risk (T1 ACE and T3 VEGF-A), intermediate risk (T2 ACE and T2 VEGF-A) and low risk (T3 ACE and T1 VEGF-A).
Fig 2: Prognostic value of basal VEGF-A and ACE plasma levels in the first-line treatment of mCRC patients with chemotherapy plus bevacizumab: (A) effect of basal VEGF levels on PFS outcome; (B) effect of basal VEGFA levels on OS outcome; (C) effect of basal ACE levels on PFS outcome; and (D) effect of basal ACE plasma levels on OS outcome.
Supplier Page from Abcam for Human ACE ELISA Kit (CD143)